Wednesday, Apr 24 2024 | Time 12:48 Hrs(IST)
image
Business EconomyPosted at: Jun 15 2021 12:13PM


Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler

Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name - Tiogiva® in UK
Tiogiva® is the bioequivalent version of Boehringer Ingelheim's Spiriva® Handihaler®
Tiotropium Bromide DPI is used in the treatment of chronic obstructive pulmonary disease (COPD)
Glenmark has a strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and UK
Glenmark is also planning to launch the product across other markets in Western Europe in future
Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020
MUMBAI, India, June 15, 2021 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva®, in UK for the treatment of chronic obstructive pulmonary disease (COPD).
Glenmark Logo
COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult. There are many different types of the condition, although little is known about what causes this variation and the best way to manage the different versions of the disease1.
According to data from IQVIA, Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020.
Glenmark's subsidiary, Glenmark Pharmaceuticals Europe Limited had entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and UK in August 2018. Glenmark is planning subsequent launches of the product across markets in Western Europe under the brand name Tiogiva® in Ireland, Sweden, Finland and Norway; Tavulus® in Denmark, Spain and Netherlands; and Tiotropium Glenmark® in Germany.
Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim's Spiriva® Handihaler® and is used in the treatment of COPD.
This is the second inhalation product in-licensed by Glenmark for the European market after Stalpex® (Fluticasone/ Salmeterol) dry powder inhaler.
"We are glad to introduce Tiogiva®, one of the first bioequivalent drugs to be launched in Europe for treatment of COPD. Respiratory medicine is a key area of focus for Glenmark and the launch of this product will enable us to improve access to COPD treatment by providing an effective and high quality treatment option to patients in UK and Western Europe," said Achin Gupta, EVP & Business Head of EMEA-L, Glenmark Pharmaceuticals Ltd.
About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It ranks among the world's top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa's Generics Bulletin). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world's most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. For more information, visit www.glenmarkpharma.com
(Disclaimer--Features may vary depending on the regions; subject to change without notice.)
References:
1 https://europeanlung.org/en/information-hub/lung-conditions/copd/
Logo: http://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg
Please log in to get detailed story.
Tags: #Glenmark launches Tiogiva®# becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler
More News
SBI Card launches SBI Card MILES for Travel enthusiast

SBI Card launches SBI Card MILES for Travel enthusiast

24 Apr 2024 | 12:39 PM

Mumbai, April 24 (UNI) SBI Card, India’s largest pure-play credit card issuer, has launched three variants of its first travel-focused core credit card, ‘SBI Card MILES’.

see more..
Sensex up over 200 points

Sensex up over 200 points

24 Apr 2024 | 10:39 AM

Mumbai, April 24 (UNI) The BSE Sensex remained firm for the fourth straight session on Wednesday, surging 261 points at 74,000 in opening session as buying was seen across board amid positive Asian Market.

see more..
Rupee up 6 paise against USD

Rupee up 6 paise against USD

24 Apr 2024 | 10:32 AM

Mumbai, Apr 24 (UNI) The rupee remained strong on Wednesday, advancing 6 paise to 83.28 against the opening session on selling of US dollars by bankers and exporters, dealers at the Foreign Exchange said.

see more..

USD, Yen down; Pound, Euro up

24 Apr 2024 | 10:15 AM

Mumbai, Apr 24 (UNI) Following were the indicative currency rates and travellers' cheques
buying and selling rates.

see more..

High taxation and extreme regulations undermine legal cigarette industry in India

23 Apr 2024 | 7:48 PM

Hyderabad, April 23 (UNI) The high taxation and extreme regulations have resulted the share of legal cigarettes in total tobacco consumption in the country has shrunk by 37 per cent to a mere 9 per cent at the present from 21 per cent in 1981-82, according to the Tobacco Institute of India (TII).

see more..
image